Mutations within the cholecystokinin-B/gastrin receptor ligand 'pocket' interconvert the functions of nonpeptide agonists and antagonists

Molecular Pharmacology

Volumn 54, Issue 5, 1998, Pages 857-863

  Bläker, Michael ^a   Ren, Yong ^a   Gordon, Michelle C ^a   Hsu, Jean E ^a   Beinborn, Martin ^a   Kopin, Alan S ^a,b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,3 DIHYDRO 1 METHYL 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL) 3 (3 METHYLPHENYL)UREA; 1 [2,3 DIHYDRO 1 (2' METHYLPHENACYL) 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL] 3 (3 METHYLPHENYL)UREA; 1 [5 (3 AZABICYCLO[3.2.2]NON 3 YL) 2,3 DIHYDRO 1 METHYL 2 OXO 1H 1,4 BENZODIAZEPIN 3 YL] 3 (3 METHYLPHENYL)UREA; CHOLECYSTOKININ B RECEPTOR; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; GASTRIN RECEPTOR;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; DRUG RECEPTOR BINDING; GASTROINTESTINAL DISEASE; GENE MUTATION; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

EID: 0031785214     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.54.5.857     Document Type: Article

References (39)

1. Baldwin JM (1993) The probable arrangement of the helices in G protein-coupled receptors. EMBO (Eur Mol Biol Organ) J 12:1693-1703.
2. 1 receptor activation is dependent upon two juxtaposed asparagine residues on transmembrane helices III and VII. J Biol Chem 272:4245-4251.
3. Beinborn M, Lee YM, McBride EW, Quinn SM, and Kopin AS (1993) A single amino acid of the cholecystokinin-B/gastrin receptor determines specificity for non-peptide antagonists. Nature (Lond) 362:348-350.
4. Beinborn M, Quinn SM, and Kopin AS (1998) Minor modifications of a CCK-B/gastrin receptor non-peptide antagonist confer a broad spectrum of functional properties. J Biol Chem 273:14146-14151.
5. Caron MG and Lefkowitz RJ (1993) Catecholamine receptors: structure, function, and regulation. Recent Prog Horm Res 48:277-290.
6. Claude PA, Wotta DR, Zhang XH, Prather PL, McGinn TM, Erickson LJ, Loh HH, and Law PY (1996) Mutation of a conserved serine in TM4 of opioid receptors confers full agonist properties to classical antagonists. Proc Natl Acad Sci USA 93:5715-5719.
7. Dryja TP, Berson EL, Rao VR, and Oprian DD (1993) Heterozygous missense mutation in the rhodopsin gene as a cause of congenital stationary night blindness. Nature Genet 4:280-283.
8. Faris PL, Komisaruk BR, Watkins LR, and Mayer DJ (1983) Evidence for the neuropeptide cholecystokinin as an antagonist of opiate analgesia. Science (Washington DC) 219:310-312.
9. Farrens DL, Altenbach C, Yang K, Hubbel WL, and Khorana HG (1996) Requirement of rigid-body motion of transmembrane helices for light activation of rhodopsin. Science (Washington DC) 274:768-770.
10. Goodman LS and Gilman A (1990) The Pharmacological Basis of Therapeutics, 8th ed. Pergamon, Elmsford, NY.
11. 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. J Biol Chem 268:23116-23121.
12. 1A angiotensin II receptor induces its constitutive activation. J Biol Chem 272:1822-1826.
13. B/gastrin receptors. Ann NY Acad Sci 713:283-297.
14. Ishii I, Izumi T, Tsukamoto H, Umeyama H, Ui M, and Shimizu T (1997) Alanine exchanges of polar amino acids in the transmembrane domains of platelet-activating factor receptor generate both constitutively active and inactive mutants. J Biol Chem 272:7846-7854.
15. Ji Z, Hadac EM, Henne RM, Patel SA, Lybrand TP, and Miller LJ (1997) Direct identification of a distinct site of interaction between the carboxyl-terminal residue of cholecystokinin and the type A cholecystokinin receptor using photoaffinity labeling. J Biol Chem 272:24393-24401.
16. Kato T, Wang ZW, Zoega T, and Crowe RR (1996) Missense mutation of the cholecystokinin B receptor gene: lack of association with panic disorder. Am J Med Genet 67:401-405.
17. Kenakin T (1997) Agonist-specific receptor conformations. Trends Pharmacol Sci 18:416-417.
18. Kennedy K, Gigoux V, Escrieut C, Maigret B, Martinez J, Moroder L, Frehel D, Gully D, Vaysse N, and Fourmy D (1997) Identification of two amino acids of the human cholecystokinin-A receptor that interact with the N-terminal moiety of cholecystokinin. J Biol Chem 272:2920-2926.
19. Kopin AS, McBride EW, Gordon MC, Quinn SM, and Beinborn M (1997) Inter-and intraspecies polymorphisms in the choiecystokinin-B/gastrin receptor alter drug efficacy. Proc Natl Acad Sci USA 94:11043-11048.
20. Kopin AS, McBride EW, Quinn SM, Kolakowski LF Jr and Beinborn M (1995) The role of the cholecystokinin-B/gastrin receptor transmembrane domains in determining affinity for subtype-selective ligands. J Biol Chem 270:5019-5023.
21. Langhans N, Rindi R, Chiu M, Rehfeld JF, Ardman B, Beinborn M, and Kopin AS (1997) Abnormal gastric histology and decreased acid production in cholecystokinin-B/gastrin receptor-deficient mice. Gastroenterology 112:280-286.
22. Nagata A, Ito M, Iwata N, Kuno J, Takano H, Minowa O, Chihara K, Matsui T, and Nada T (1996) G protein coupled cholecystokinin-B/gastrin receptors are responsible for physiological cell growth in the stomach mucosa in vivo. Proc Natl Acad Sci USA 93:11825-11830.
23. Nishida A, Miyata K, Tsutsumi R, Yuki H, Akuzawa S, Kobayashi A, Kamato T, Ito H, Yamano M, Katuyama Y, Satoh M, Ohta M, and Honda K (1994) Pharmacological profile of (R)-1,1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo-5-phenyl-1H-1,4-benzodiazepin- 3-yl]-3-(3-methylphenyl)urea (YM022), a new potent and selective gastrin/cholecystokinin-B receptor antagonist, in vitro and in vivo. J Pharmacol Exp Ther 269:725-731.
24. Ravard S and Dourish CT (1990) Cholecystokinin and anxiety. Trends Pharmacol Sci 11:271-273.
25. Reihsaus E, Innis M, MacIntyre N, and Liggett SB (1993) Mutations in the gene encoding for the beta 2-adrenergic receptor in normal and asthmatic patients. Am J Respir Cell Mol Biol 8:334-339.
26. Robbins LS, Nadeau JH, Johnson KR, Kelly MA, Roselli-Rehfuss L, Baack E, Mountjoy KG, and Cone RD (1993) Pigmentation phenotypes of variant extension locus alleles result from point mutations that alter MSH receptor function. Cell 72:827-834.
27. Scheer A, Fanelli F, Costa T, De Benedetti PG, and Cotecchia S (1996) Constitutively active mutants of the alpha 1B-adrenergic receptor: role of highly conserved polar amino acids in receptor activation. EMBO J 15:3566-3578.
28. Schertler GFX, Villa C, and Henderson R (1993) Projection structure of rhodopsin. Nature (Lond) 362:770-772.
29. Schmitz F, Pratt D, Wu M-J, Kolakowski LF Jr, Beinborn M, and Kopin AS (1996) Identification of cholecystokinin-B/gastrin receptor domains that confer high gastrin affinity: utilization of a novel Xenopus laevis Cholecystokinin receptor. Mol Pharmacol 50:436-441.
30. Schwartz TW, Gether U, Schambye HT, and Hjorth SA (1995) Molecular mechanism of action of non-peptide ligands for peptide receptors. Curr Pharm Design 1:325-342.
31. Sheikh SP, Zvyaga TA, Lichtarge O, Sakmar TP, and Bourne HR (1996) Rhodopsin activation blocked by metal-ion-binding sites linking transmembrane helices C and F. Nature (Lond) 383:347-350.
32. Shenker A, Laue L, Kosugi S, Merendino JJ, Minegishi T, and Cutler GB (1993) A constitutively activating mutation of the luteinizing hormone receptor in familial male precocious puberty. Nature (Lond) 365:652-654.
33. Silvente-Poirot S and Wank SA (1996) A segment of five amino acids in the second extracellular loop of the cholecystokinin-B/gastrin receptor is essential for the selectivity of the peptide agonist gastrin. J Biol Chem 271:14698-14706.
34. Singh L, Lewis AS, Field MJ, Hughes J, and Woodruff GN (1991) Evidence for an involvement of the brain Cholecystokinin B receptor in anxiety. Proc Natl Acad Sci USA 88:1130-1133.
35. Strader CD, Candelore MR, Hill WS, Dixon RAF, and Sigal IS (1989a) A single amino acid substitution in the β-adrenergic receptor promotes partial agonist activity from antagonists. J Biol Chem 264:16470-16477.
36. Strader CD, Gaffney T, Sugg EE, Candelore MR, Keys R, Patchett AA, and Dixon RAF (1991) Allele-specific activation of genetically engineered receptors. J Biol Chem 266:5-8.
37. Strader CD, Sigal IS, and Dixon RA (1989b) Genetic approaches to the determination of structure-function relationships of G protein-coupled receptors. Trends Pharmacol Sci 10(suppl):26-30.
38. Wank SA (1995) Cholecystokinin receptors. Am J Physiol 269:G628-G646.
39. Wiertelak EP, Maier SF, and Watkins LR (1992) Cholecystokinin antianalgesia: safety clues abolish morphine analgesia. Science (Washington DC) 256:830-833.